with chromosomal abnormalities, and about half of them carry FLT3-ITD. Chronic phase CML is NPM1 wt , whereas only one case of NPM1 mut myeloid blast crisis CML has been reported.
IDH1 and IDH2 mutations are also not found in chronic phase CML but can be found at low frequency in blast crisis CML. 11 Here, we present a CML patient who developed clonal hematopoietic disease (AML) in PhÀ cells, with normal karyotype and NPM1 mut , while being in complete CML molecular remission and without previous MDS phase or CCA/PhÀ. The development of PhÀ AML could be the result of inherent genomic instability or a direct effect of TKI therapy, whereas the possibility that AML occurred by chance cannot be excluded. It is should be stressed that sensitive RQ-PCR assay could detect NPM1 mut transcripts 1 year before overt AML, implying that the development of NPM1 mut AML was a slow process. He relapsed twice with clonal evolution: IDH2 R140Q mutation at first relapse and complex karyotype at second relapse. To our knowledge, this is the first report of normal karyotype NPM1 Chronic lymphocytic leukaemia (CLL) is considered to arise from a failure of apoptosis and an accumulation of CD5 þ CD23 þ mature B-cells, although significant levels of cell division underlie the clonal growth of these cells. This is apparent from deuterated water incorporation experiments 1 as well as telomere erosion. [2] [3] [4] We have recently shown that the telomere erosion observed in CLL patients is extensive and can result in the loss of telomere function resulting in telomeretelomere fusion events, some of which were clonal; 5 this work also revealed telomeric loss of heterozygosity as well as largescale genomic rearrangements that were concomitant with telomere dysfunction. Telomere dysfunction may therefore account for clonal evolution and the occurrence of large-scale genomic rearrangements, including the loss of 17p and 11q, that confer a poor prognosis and are associated with short telomeres.
3 Short telomeres and telomeric DNA damage are also associated with the development of resistance to DNA damage-induced apoptosis. 6 The telomere dynamics described in CLL are indistinguishable from those observed experimentally in fibroblast cells undergoing a telomere driven 'crisis' in culture following the abrogation of the p53 pathway. 5 In this situation, the loss of cell cycle checkpoints in response to DNA doublestrand breaks (DSBs) facilitates the ongoing cell division beyond the point that would normally trigger telomere-dependent replicative senescence. It is clear from these in vitro studies that there is a subtle distinction between the length of telomere that elicits a cell cycle checkpoint response, triggering p53-dependent replicative senescence or apoptosis and the shorter telomeres that are capable of fusion in cells undergoing 'crisis'. 5 Based on these observations, we hypothesised that in order for CLL cells to achieve substantial telomere erosion and dysfunction they must be compromising in their ability to Letters to the Editor mediate cell cycle checkpoints in response to the DSBs that arise from telomere shortening and uncapping. 7 A key mediator of the cellular response to DSBs is the protein encoded by the ATM tumour-suppressor gene, mutations that confer a marked defect in cell cycle checkpoints and subtle defects in the ability of the cells to repair DSBs. 7 ATM plays a key role in DNA damage signalling by p53 specifically in response to DSBs, including those observed at dysfunctional telomeres. 7 ATM is frequently inactivated in CLL and this confers a poor clinical response. 8 Here we examined whether ATM modulates telomere dynamics in CLL B-cells.
Poor prognosis subsets of CLL patients often display defects in the p53 pathway characterised by mutations in ATM or P53.
8
CLL B-cells with ATM mutations exhibit a defective p53 response to, and an inability to efficiently repair, DSBs induced by ionising radiation. 8 In order to study the role of ATMdependent DNA damage checkpoints in facilitating telomere erosion and dysfunction in CLL, we analysed a cohort of CLL patients (n ¼ 61, Table 1 ). ATM status was defined by sequence analysis of the ATM gene 8 and included the following genotypes, ATM wild type/ATM wild type (n ¼ 20), ATM wild type/11q deletion (n ¼ 9), ATM mutation/ATM wild type (n ¼ 9), ATM mutation/11q deletion (n ¼ 7) and ATM mutation/ATM mutation (n ¼ 3) (Supplementary Table 1 ). The results were further compared with a cohort of stage C patients in which the ATM status was not known (n ¼ 13). We determined telomere length using single telomere length analysis, which can detect the presence of extremely short telomeres of the length at which telomere fusion can occur; 5 telomeres of this length are not represented in the other telomere length assays. We analysed the telomeres of the 17p and 11q chromosome arms that contain the p53 and ATM genes, respectively as well as the XpYp telomere ( Figure 1 ). There was a substantial difference in telomere length at all the three chromosome ends between the ATM-mutated and wild-type cohorts (Po0.0001, t-test, Figure 2a ). Telomere lengths in the ATM-mutated cohort were extremely short and homogeneous with an overall combined telomere length of 2.02 ± 0.79 kb (mean ± s.d.). The minimum telomere length was 0.44 kb and the maximum was 4.1 kb, a mean difference of 2.89 kb compared with the ATM wild-type cohort (Po0.0001, mean 4.91±1.33 kb, minimum 2.81 kb, maximum 8.38 kb). We detected no statistically significant differences in the telomere length as a function of the nature of the ATM mutations; the 11q-deleted/ATM wild-type samples showed subtly longer telomeres than those with defined monoor bi-allelic mutation in ATM, however, this was not statistically significant ( Figure 2c ). We have previously described short telomeres in Binet stage C CLL patients, the majority of which were prone to telomere fusion events. 5 Comparison of this data set with the ATM-mutated cohort at the XpYp and 17p telomeres revealed that ATM mutation confers more homogeneous and extensive telomere erosion, a difference of 0.56 kb (2.58 vs 2.03 kb, P ¼ 0.038, Figures 2a and b) . Together, these data Letters to the Editor provide a clear demonstration that CLL B-cells exhibiting ATM mutations display extreme telomere shortening, with telomeres in the length range at which telomere fusion has been detected in both in vitro cell culture and ex vivo.
5
Within the ATM-mutated and wild-type cohorts there was no difference between the mean telomere lengths determined at all the three chromosome ends (wild type P ¼ 0.98, mutant P ¼ 0.14, ANOVA, Figure 2a ). These data indicate that there were no differential rates of erosion at specific chromosome ends and thus it is unlikely that chromosome-specific telomere dynamics drive the loss of specific chromosome ends. These data, together with our previous analysis of specific telomeres with single telomere length analysis and the correlation of single telomere length analysis data with genome wide telomere length analysis, 5 indicate that a single telomere is sufficient to represent the genome wide telomere length distributions.
We previously observed a subset of Stage A patients that exhibited telomeres of similar length to those observed in stage C patients, indicating that telomere erosion can precede disease progression. 5 In our cohort, patients with ATM mutations were identified in all stages of disease (Figure 3a) . Of all the Stage A patients analysed, only those exhibiting ATM mutations displayed the shortest telomere length profiles (Po0.0001, Figures 3a and b) ; these were slightly longer (mean 2.49 kb) compared with ATM-mutated stage B and C patients (mean 1.81 kb, P ¼ 0.10 and 1.65 kb, P ¼ 0.055, respectively). In the stage A cohort, the telomere erosion observed in the presence of ATM mutations, including ATM wild type/11q deletion, was independent of IGHV gene mutation status (P ¼ 0.17, Figure 3c ), CD38 status (P ¼ 0.10, Figure 3d ) and ZAP70 status (P ¼ 0.30, Figure 3e ). Unmutated IGHV genes are over-represented in 11q-deleted CLL patients, however, telomere erosion was still independent following the exclusion of these patients (IGHV, P ¼ 0.71; CD38, P ¼ 0.10; ZAP70, P ¼ 0.68). These data show that the extreme telomere shortening observed in the ATM patient cohort is independent of disease stage as well as the commonly used markers of progression. ATM mutation is therefore associated with significant telomere erosion prior to disease progression.
Telomere length heterogeneity can be indicative of clonal growth. 5 The telomere length profiles of ATM-mutated cohort were significantly less heterogeneous compared with the ATM wild-type cohort (Po0.0001, Figure 3f) , consistent with the outgrowth of a dominant ATM mutant clone in these patients. The reduction in telomere length heterogeneity in the ATM-mutated cohort indicates that ATM mutation has no impact on the frequency of stochastic telomeric deletion and mutation, which would be predicted to increase telomere length heterogeneity with ongoing cell division. The role that ATM has in conferring telomere function is not fully understood, shorter telomeres and telomere fusion have been documented in AT patients and mouse models. 7 In addition, the ATM homologues in yeast TEL1 and MEC1 have a role in providing protection from exonuclease activity and telomere length maintenance in the presence of telomerase in yeast and Arabidopsis. 7 It is not clear from our data whether or not the absence of ATM causes a resetting of telomeres to a shorter length in CLL B-cells or if it facilitates accelerated rates of telomere erosion as a function of cell division. However, irrespective of whether ATM mutations alter telomere dynamics, our data are consistent with the view that compromised DSB checkpoints, as documented in ATM-mutated cells including both fibroblasts and CLL B-cells, facilitate extended replication and extreme telomere shortening beyond the point that would normally trigger a p53-dependent DSB response. In contrast to CLL B-cells exhibiting mono-or bi-allelic ATM mutation, those with ATM wild type/11q deletion display wild-type levels of ATM S1981 auto-phosphorylation, p53 S15 phosphorylation and PARP1 cleavage, following exposure to ionising radiation. 8 The ATM wild type/11q deletion cases exhibited similar levels of telomere erosion compared with those of ATM mutations, indicating the possibility that the loss of 11q affects additional pathways modulating replicative lifespan or that telomere loss may represent a more sensitive marker of ATM haploinsufficiency. It will be informative to understand the impact of the loss of p53 and other genes involved in the response to DSBs on the telomeres of CLL B-cells. n Statistically significant differences compared with controls without added sensitizing proteins (Po0.05).
